Science reshapes the future
A Canadian Regenerative Medicine Company
"In my opinion, Dr. Koch and his team have a novel plan based on good science to develop a licensable and commercially-available allogeneic MSC product for veterinary use.” “I was also compelled by eQcell’s translational approach using animal data to inform similar human cell therapies which I believe hold tremendous promise to improve human health in addition to equine welfare... I have favored the One Health concept for years, so it is very exciting to be part of a company pursuing this strategy.”
Dr. C. Wayne McIlwraith
Distinguished Professor and Founding Director, Colorado State University's Orthopedic Research Center
eQcell Inc. is Canada’s premier clinical-stage regenerative medicine company addressing conditions and diseases affecting sporting and domestic animals globally for which current treatments are ineffective, not fully effective, or palliative. eQcell has developed allogeneic equine cord blood stem cells as well as canine adipose-derived mesenchymal stromal cells designed to provide veterinarians around the world with off-the-shelf therapeutics with increased efficacy and predictability over the current, laborious and expensive autologous stem cell treatments that extract, expand and re-inject a horse's own cells.
Mesenchymal stromal cells have demonstrated safety and efficacy in the treatment and resolution of diseases and conditions for which the treatment options are ineffective, not fully effective, or palliative.
Science & Innovation
While still in its early stages, the efficacy of numerous regenerative applications is firmly established.
The vast potential promises to change surgical and non-surgical care allowing for unprecedented personalized medical interventions